|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
DESMOPRESSIN ANTIDIURETIC EFFECT IS REDUCED BY THE DRUG
|
DEXTROPROPOXYPHENE MAY REDUCE ITS METABOLISM LEADING TO ITS INCREASED SERUM LEVELS AND TOXICITY
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
DISULFIRAM MAY CAUSE ACUTE ORGANIC BRAIN SYNDROME
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
CONCURRENT USE WITH ASTEMIZOLE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
TRICYCLIC ANTIDEPRESSANTS MAY POTENTIATE THE EFFECTS OF MUSCLE RELAXANTS
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
CALCIUM CHANNEL BLOCKERS MAY REDUCE THE METABOLISM OF OTHER DRUG LEADING TO ITS INCREASED SERUM CONCENTRATION AND TOXICITY
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
INCREASED SEDATIVE EFFECT
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
TRICYCLIC ANTIDEPRESSANTS MAY REDUCE THE ANTIHYPERTENSIVE EFFECTS OF THE DRUG
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
FLUOXETINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|